inhibitor (tyrosine kinase inhibitor, angiogenesis inhibitor, VEGF inhibitor)
FDA Approval: Sorafenib was approved by the US
Food and Drug Administration (FDA) in 2005 for the treatment of renal cell carcinoma, a form of kidney
Sorafenib is available by prescription only
Sorafenib is indicated for the treatment of these two cancers:
carcinoma (also called malignant hepatoma), a form of liver cancer
cancer after failure of prior
treatment with interferon alfa or interleukin-2 (IL-2), or in
patients for whom these treatments are considered inadequate.
Sorafenib can be prescribed to treat
other medical conditions not listed in this article; contact your doctor or pharmacist for more
form: Sorafenib comes as a tablet to be
taken by mouth
to prescribe you an
effective dosage of Sorafenib, your oncologist will consider the type and severity of the cancer, whether or
not you are taking other medications, your health status, and your body surface area (BSA).
Usually, the recommended dosage for adults is 400 mg, taken by mouth 2 times a
day with water. Take the medication without food, one hour before or 2 hours after a meal. If you take Sorafenib
with a meal, make sure its fat content is low. Take Sorafenib at around the same times every day. Swallow the
tablets whole with a full glass of water; do not chew or crush them.
cases, your doctor may recommend a different dosage; it is important that you do not change the dosage or stop
the treatment without first consulting your doctor. Taking Sorafenib more or less may cause serious health
problems, or lower its curative effect.
Overdose: as with any drug, Sorafenib overdose
can be dangerous if taken for a long term. Chemotherapy drugs, including Sorafenib, tend to lead to a decrease
in white blood cells and platelets which puts you at risk of serious infections. Follow the directions on the
prescription label, or talk to your physician or pharmacist if you don’t understand the indication. Sorafenib is
a strong medication; take it as prescribed.
Storage: store Sorafenib at room temperature,
away from direct sunlight, moisture and heat. Keep Sorafenib and all medications out of the reach of children. Do not store Sorafenib in the bathroom. Sorafenib
and all other medications should not be used beyond the expiration date printed on the container.
your best to take Sorafenib around the same time every day.
In case you forget to take a dose, take the missed
one as soon as you remember it. However, if it is time for your next dose,
do not double the next dose to recover the missed one; it can be dangerous. Contact your doctor or wait to go back
to your regular schedule.
is contraindicated in the following conditions:
of the constituents
taking Sorafenib, tell your doctor if you experience any of the 6 following conditions; the drug may
aggravate these conditions:
b) liver disease
c) high blood
e) heart attack or heart
f) Non cancerous kidney
Mechanism of action (MOA): Sorafenib is a multikinase inhibitor;
by its antiangiogenic action, it slows or stops the growth of cancerous cells, and delay the growth of new blood
vessels that feed cancer cells.
Interactions: talk you to your doctor before taking
vitamins, nutritional supplements, or St. John's wort. Certain medication can
interact with Sorafenib. Tell your doctor or pharmacist if you are taking any of these
- Bupropion (Wellbutrin,
- Doxorubicin (Doxil,
- Methadone (Dolophine,
- Phenytoin (Dilantin,
- Rifampin (Rifadin,
Side effects: Sorafenib not only attack
cells but also healthy
cells, which often leads, in most patients, to the following side effects:
- nausea and
- ulcers in the mouth
- reduced urine
If the side
effects above persist for weeks, contact your oncologist. In addition, contact your doctor immediately if you
experience any of these symptoms:
discoloration of the
whites of the eyes
of eyes or skin
- black, tarry stools
or accelerated heartbeat
- blood in
urine or stool
associated with chills
- pain in
lower back or side
- pain or
difficulty when passing urine
of feet and lower legs
bleeding or bruising.
fda.gov, FDA Approves Sorafenib for Patients with Inoperable